Clinical Benefit from Docetaxel +/- Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy.
Qin K, Wang K, Li S, Hong L, Padmakumar P, Waree R, Hubert SM, Le X, Vokes N, Rai K, Vaporciyan A, Gibbons DL, Heymach JV, Lee JJ, Woodman SE, Chung C, Jaffray DA, Altan M, Lou Y, Zhang J.
Qin K, et al. Among authors: li s.
Cancers (Basel). 2024 Feb 26;16(5):935. doi: 10.3390/cancers16050935.
Cancers (Basel). 2024.
PMID: 38473297
Free PMC article.